<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>21 Myelodysplasia</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-20-chronic-myeloid-leukaemia.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 52.5%;"></div>
                        </div>
                       <span class="progress-text">Lecture 21 of 40</span>
                    </div>
                    <a href="haematology-22-acute-leukaemia.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">21 Myelodysplasia</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <section id="mds-intro" class="content-section" aria-labelledby="section-heading-1">
                    <div class="content-card">
                        <p>This is a clonal disorder of the haemopoietic stem cell characterized by peripheral blood cytopenias affecting more than one lineage in association with a cellular marrow, indicating ineffective haempoiesis.</p>
                    </div>
                </section>

                <section id="aetiology-pathogenesis" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                        <span class="heading-text">Aetiology and pathogenesis</span>
                    </h2>
                    <div class="content-card">
                        <p>Myelodysplasia (MDS) may be primary (de novo) or a consequence of previous chemotherapy/radiotherapy (secondary). Various chromosome and oncogene abnormalities occur, e.g. complete or partial deletions of chromosomes 5 or 7, point mutations in RAS oncogenes. The disease is divided into five subgroups (Table 21.1). It may transform to acute myeloid leukaemia (AML) (&gt;30% blasts in the marrow).</p>
                    </div>
                </section>

                <section id="clinical-features" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                        <span class="heading-text">Clinical features</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Most frequent in the elderly but young adults or even children may be affected.</li>
                            <li>Bone marrow failure (see Chapter 18) with anaemia and/or leucopenia and/or thrombocytopenia.</li>
                            <li>In chronic myelomonocytic leukaemia (CMML), the spleen may be enlarged.</li>
                            <li>The 5q-syndrome is a subgroup, occurring particularly in elderly females with a high platelet count, macrocytosis and good prognosis.</li>
                        </ul>
                    </div>
                </section>

                <section id="laboratory-findings" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                        <span class="heading-text">Laboratory findings</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Anaemia is usually macrocytic.</li>
                            <li>Neutropenia is frequent and neutrophils may be hypogranular with pseudo-Pelger forms. Monocytes are increased in CMML to &gt;1.0 x 10<sup>9</sup>/L.</li>
                            <li>Bone marrow is usually hypercellular but may be hypocellular and/or fibrotic.</li>
                            <li>Characteristic morphological changes are seen in all three lineages (Figs 21.1-21.4).</li>
                        </ul>
                    </div>
                </section>

                <section id="differential-diagnosis" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                        <span class="heading-text">Differential diagnosis</span>
                    </h2>
                    <div class="content-card">
                        <p>This is very broad, particularly when only one lineage is involved in an elderly person. Thus, other causes of anaemia, e.g. haematinic deficiency, renal disease, hypothyroidism, anaemia of chronic disease must be excluded; some or all may coexist with MDS. Thrombocytopenia or leucopenia may be caused by drugs, immune destruction or hypersplenism. The hallmark of MDS is involvement of more than one—typically all three—lineage(s). Nevertheless, distinction between MDS, myelofibrosis and aplasia may be difficult in patients with pancytopenia. The finding of a cytogenetic abnormality greatly strengthens what may otherwise be a subjective morphological diagnosis.</p>
                    </div>
                </section>

                <section id="course-prognosis" class="content-section" aria-labelledby="section-heading-6">
                    <h2 id="section-heading-6" class="section-heading">
                        <span class="heading-text">Course and prognosis</span>
                    </h2>
                    <div class="content-card">
                        <p>This depends on the type of MDS (see Table 21.1). The degree of cytopenia influences the incidence of complications and treatment, while the percentage of blast cells is predictive of the risk of developing acute leukaemia. Death may be caused by infection, haemorrhage, iron overload from multiple transfusions or from transformation into AML.</p>
                        
                        <div class="table-container">
                             <table class="content-table">
                                 <caption>Table 21.1 Classification of the myelodysplastic syndromes.</caption>
                                 <thead>
                                     <tr>
                                         <th>Disease</th>
                                         <th>Peripheral blood</th>
                                         <th>Bone marrow</th>
                                         <th>Approximate median survival (months)</th>
                                     </tr>
                                 </thead>
                                 <tbody>
                                     <tr>
                                         <td>1 Refractory anaemia*</td>
                                         <td>Blasts &lt; 1%</td>
                                         <td>Blasts &lt;5%</td>
                                         <td>50</td>
                                     </tr>
                                     <tr>
                                         <td>2 RA with ring sideroblasts</td>
                                         <td>Blasts &lt;1%</td>
                                         <td>Blasts &lt;5%<br>Ring sideroblasts &gt;15% of total erythroblasts</td>
                                         <td>50</td>
                                     </tr>
                                     <tr>
                                         <td>3 RAEB</td>
                                         <td>Blasts &lt;5%</td>
                                         <td>Blasts 5-20%</td>
                                         <td>11</td>
                                     </tr>
                                     <tr>
                                         <td>4 RAEB-t</td>
                                         <td>Blasts &gt;5%</td>
                                         <td>Blasts 20-30% or Auer rods present</td>
                                         <td>5</td>
                                     </tr>
                                     <tr>
                                         <td>5 CMML</td>
                                         <td colspan="3">As any of the above with &gt;1.0 x 10<sup>9</sup>/L monocytes</td>
                                     </tr>
                                 </tbody>
                                 <tfoot>
                                    <tr>
                                        <td colspan="4" style="font-size: 0.9em; padding-top: 1em;">*In some cases neutropenia or thrombocytopenia is present without anaemia. These cases are termed refractory anaemia. CMML, chronic myelomonocytic leukaemia; RA, refractory anaemia; RAEB, RA with excess blasts; RAEB-t, RAEB in transformation.</td>
                                    </tr>
                                 </tfoot>
                             </table>
                        </div>
                    </div>
                </section>

                <section id="treatment" class="content-section" aria-labelledby="section-heading-7">
                    <h2 id="section-heading-7" class="section-heading">
                        <span class="heading-text">Treatment</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Support care with red cell or platelet transfusions and antimicrobials may be required.</li>
                            <li>Iron chelation therapy may be needed for multiply transfused iron loaded patients with an otherwise good prognosis.</li>
                            <li>Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) may be used temporarily to increase neutrophil and monocyte production; erythropoietin produces a rise in haemoglobin in about 5-15% of patients with RA.</li>
                            <li>Chemotherapy with low-dose ara-C, etoposide, thioguanine or 6-mercaptopurine is used to control excess blast proliferation in patients unsuitable for high-dose chemotherapy.</li>
                            <li>Younger patients with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEB-t) may be treated as AML. Fludarabine, ara-C, G-CSF ± idarubicin (FLAG ± Ida) is a useful form of combination chemotherapy. Complete remissions are less frequent than in de novo AML. Allogeneic SCT (sibling or MUD) may cure younger patients.</li>
                        </ul>
                        
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-058-1.jpg" alt="Fig. 21.1 Peripheral blood film in myelodysplasia showing hypogranular neutrophils with bi-lobed nuclei (pseudo-Pelger cells)." class="content-image">
                            <figcaption>Fig.21.1 Myelodysplasia: peripheral blood film showing hypogranular neutrophils with bi-lobed nuclei (pseudo-Pelger cells).</figcaption>
                        </figure>

                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-058-4.jpg" alt="Fig. 21.4 Bone marrow aspirate in myelodysplasia showing an erythroblast and an abnormal normoblast, indicative of dyserythropoiesis." class="content-image">
                            <figcaption>Fig. 21.4 Myelodysplasia: bone marrow aspirate showing an erythroblast and abnormal normoblast (dyserythropoiesis). Ringed sideroblasts (see Fig. 10.3) may also occur.</figcaption>
                        </figure>

                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-058-2.jpg" alt="Fig. 21.2 Bone marrow aspirate in myelodysplasia showing a granular blast cell with blue cytoplasm and hypogranular maturing myeloid cells." class="content-image">
                            <figcaption>Fig.21.2 Myelodysplasia: bone marrow aspirate showing a granular bast with blue cytoplasm and hypogranular maturing myeloid cells.</figcaption>
                        </figure>

                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-058-3.jpg" alt="Fig. 21.3 Bone marrow aspirate in myelodysplasia showing mononuclear and binuclear micromegakaryocytes." class="content-image">
                            <figcaption>Fig.21.3 Myelodysplasia: bone marrow aspirate showing mononuclear and binuclear micromegakaryocytes.</figcaption>
                        </figure>
                    </div>
                </section>

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-20-chronic-myeloid-leukaemia.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 52.5%;"></div>
                        </div>
                       <span class="progress-text">Lecture 21 of 40</span>
                    </div>
                    <a href="haematology-22-acute-leukaemia.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>